This early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they'r…
Phase: PHASE1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC